Use of an illegal syringe exchange and injection-related risk behaviors among street-recruited injection drug users in Oakland, California, 1992 to 1995

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 18, Issue 5, 1998, Pages 505-511

  Bluthenthal, Ricky N ^a   Krai, Alex H ^a   Erringer, Elizabeth A ^a   Edlin, Brian R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HIV Prevention; HIV risk behaviors; Injection drug users; Injection supply sharing; Syringe exchange programs; Syringe sharing

Indexed keywords

ADULT; ARTICLE; CAUCASIAN; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; RACE DIFFERENCE; STATISTICAL ANALYSIS; SYRINGE;

EID: 0032529426     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199808150-00013     Document Type: Article

References (52)

1. Hagan H, Des Jarlais DC, Purchase D, Ried T, Friedmand SR. The Tacoma syringe exchange. J Addict Dis 1991;10:81-8.
2. Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA 1994;271:115-20.
3. Paone D, Caloir S, Shi Q, Des Jarlais DC, Sex, drugs, and syringe exchange in New York City: women's experience. J Am Med Womens Assoc 1995;50:109-14.
4. Schoenbaum EE, Hartel DM, Gourevitch MN. Needle exchange use among a cohort of injecting drug users. AIDS 1996;10:1729-34.
5. Vlahov D, Junge B, Brookmeyer R, et al. Reductions in high-risk drug use behaviors among participants in the Baltimore needle exchange program. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:400-6.
6. Kaplan EH. A method for evaluating needle exchange programmes. Stat Med 1994;13:2179-87.
7. Hagan H, Des Jarlais DC, Friedman SR, Purchase D, Alter MJ. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health 1995;85:1531-7.
8. Des Jarlais DC, Marmor M, Paone D, et al. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet 1996;348:987-91.
9. Heimer R, Khoshnood K, Jariwala Freeman B, Duncan B, Harima Y. Hepatitis in used syringes: the limits of sensitivity of techniques to detect HBV DNA, HCV RNA, and antibodies to HB core and HCV antigens. J Infect Dis 1996;173:997-1000.
10. Heimer R. Can syringe exchange serve as a conduit to substance abuse treatment? J Subst Abuse Treat 1998;15:183-91.
11. Perlman D, Perkins MP, Solomon N, Kochems L, Des Jarlais DC, Paone D. Tuberculosis screening at a syringe exchange program. Am J Public Health 1997;87:862-3.
12. Guydish J, Bucardo J, Young M, Woods W, Grinstead O, Clark W. Evaluating needle exchange: are there negative effects? AIDS 1993;7:871-6.
13. Centers for Disease Control and Prevention. Update: syringe-exchange programs - United States, 1996. MMWR Morb Mortal Wkly Rep 1997;46:565-8.
14. Lurie P, Reingold AL, Bowser B, et al. The public health impact of needle exchange programs in the United States and abroad. San Francisco: University of California Press, 1993.
15. Gostin LO, Lazzarini Z, Jones TS, Flaherty K. Prevention of HIV/ AIDS and other blood-borne diseases among injection drug users: a national survey on the regulation of syringes and needles. JAMA 1997;277:53-62.
16. Burris S, Finucane D, Gallagher H, Grace J. The legal strategies used in operating syringe exchange programs in the United States. Am J Public Health 1996;86:1161-6.
17. Bluthenthal RN. Syringe exchange as a social movement: a case study of harm reduction in Oakland, California. Subst Use Misuse 1998;33:1146-71.
18. Paone D, Des Jarlais DC, Clark J, Shi Q. United States syringe exchange program survey, 1995-1996. Presented at the 7th North American Syringe Exchange Conference, San Diego, April 24-26, 1997.
19. Bluthenthal RN, Krai AH, Lorvick J, Walters JK. Impact of law enforcement on syringe exchange programs: a look at Oakland and San Francisco. Med Anthropol 1997;18:61-83.
20. Heimer R, Bluthenthal RN, Singer M, Khoshnood K. Structural impediments to operational syringe-exchange programs. AIDS Public Policy J 1996;11:169-184.
21. Watters JK, Biernacki P. Targeted sampling: options for the study of hidden populations. Soc Probl 1989;36:416-30.
22. Bluthenthal RN, Watters JK. Multimethod research: from targeted sampling to HIV risk behaviors. In Lambert EY, Ashery RS, Needle RH, eds. Qualitative methods in the prevention of drug abuse and HIV research. Rockville, MD: National Institute on Drug Abuse, 1995.
23. National Institute on Drug Abuse. Risk behavior assessment. Rockville, MD: National Institute on Drug Abuse, 1991.
24. Centers for Disease Control and Prevention. EpiInfo, version 6. Atlanta: U.S. Department of Health and Human Services, Public Health Service, 1994.
25. Prevots DR, Hunt K, Linley L, Spruill C, Lehman JS, Gwinn M. HIV seroincidence, needle acquisition, and predictors of needle sharing among injection drug users entering drug treatment. Presented at the XI International Conference on AIDS, Vancouver, British Columbia, Canada, 1996.
26. Tortu S, Deren S, Beardsley M, Hamid R. Factors associated with needle exchange use in East Harlem, New York City. J Drug Issues 1996;26:735-49.
27. Paone D, Des Jarlais DC, Caloir S, Clark J, Jose B. Operational issues in syringe exchanges: the New York City Tagging Alternative Study. J Comm Health 1995;20:111-23.
28. Kochems L, Paone D, Des Jarlais D, Ness I, Clark J, Friedman S. The transition from underground to legal syringe exchange: the New York experience. AIDS Educ Prev 1996;8:471-89.
29. Kral A, Bluthenthal R. HIV risk behaviors among IDUs who are indirect syringe exchangers in Oakland and Richmond, CA, 1996. Presented at the 125th American Public Health Association Meetings, Indianapolis, Indiana, 1997.
30. Grund J, Kaplan C, Adriaans N. Needle sharing in the Netherlands: an ethnographic analysis. Am J Public Health 1991;81:1602-7.
31. Koester S, Booth R, Wiebel W. The risk of transmission from sharing water, drug mixing containers, and cotton filters among intravenous drug users. Int J Drug Policy 1990;1:28-30.
32. Shah SM, Shapshak P, Rivers JE, et al. Detection of HIV-1 DNA in needle/syringes, paraphernalia, and washes from shooting galleries in Miami: a preliminary laboratory report. J Acquir Immune Defic Syndr Hum Ketrovirol 1996;11:301-6.
33. Centers for Disease Control and Prevention. HIV/AIDS prevention bulletin. Atlanta, GA: Centers for Disease Control and Prevention, 1993.
34. Koester S, Booth RE, Zhang Y. The prevalence of additional injection-related HIV risk behaviors among injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:202-7.
35. Centers for Disease Control and Prevention. HIV prevention bulletin: medical advice for persons who inject illicit drugs. Atlanta: Centers for Disease Control and Prevention, 1997.
36. Watters JK, Bluthenthal RN, Kral AH. HIV seroprevalence in injection drug users [letter]. JAMA 1995;273:1178.
37. Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street- recruited injecting drug and crack cocaine users in 16 U.S. municipalities. Am J Public Health 1998;88:108-13.
38. Chaisson R, Moss A, Onishi R, Osmond D, Carlson J. Human immunodeficiency virus infection in heterosexual intravenous drug users in San Francisco. Am J Public Health 1987;77:169-72.
39. Vlahov D, Munoz A, Anthony J, Cohn S, Celentano D, Nelson K. Association of drug injection patterns with antibody to human immunodeficiency virus type 1 among intravenous drug users in Baltimore, Maryland. Am J Epidemiol 1990;132:847-56.
40. Lange W, Snyder F, Lozovsky D, et al. Geographic distribution of human immunodeficiency virus markers in parenteral drug abusers. Am J Public Health 1988;78:443-6.
41. Breakey W, Fischer P. Mental illness and the continuum of residential stability. Soc Psychiatry Psychiatr Epidemiol 1995;30: 147-51.
42. Brooner R, Greenfield L, Schmidt C, Bigelow G. Antisocial personality disorder and HIV infection among intravenous drug abusers. Am J Psychiatry 1993;150:53-8.
43. Falck R, Siegal H, Wang J, Carlson R. Usefulness of the health belief model in predicting HIV needle risk practices among injection drug users. AIDS Educ Prev 1995;7:523-33.
44. Patrick D, Strathdee S, Archibald C, et al. Determinants of HIV seroconversion in injection drug users during a period of rising prevalence in Vancouver. Int J STD AIDS 1997:437-45.
45. Brackbill R, MacGowan R, Rugg D. HIV infection risks, behaviors and methadone treatment: client-reported HIV infection in a follow-up study of injecting drug users in New England. Am J Drug Alcohol Abuse 1997;23:397-411.
46. Nelson KE, Vlahov D, Galai N, Astemborski J, Solomon L. Preparations for AIDS vaccine trials: incident human immunodeficiency virus (HIV) infections in a cohort of injection drug users in Baltimore, Maryland. AIDS Res Hum Retroviruses 1994;10(Suppl 2):S201-5.
47. Huang KHC, Watters JK, Case P. Psychological assessment and AIDS research with intravenous drug users: challenges in measurement. J Psychoactive Drugs 1988;20:191-5.
48. Latkin CA, Vlahov D, Anthony JC. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction 1993;88:517-26.
49. Vlahov D, Astemborski J, Solomon L, Nelson KE. Field effectiveness of needle disinfection among injecting drug users. J Acquir Immune Defic Syndr 1994;7:760-6.
50. Weatherby N, Needle R, Cesari H, et al. Validity of self-reported drug use among injection drug users recruited through street outreach. Eval Prog Planning 1994;17:347-55.
51. Dowling-Guyer S, Johnson ME, Fisher DG, et al. Reliability of drug users' self-reported HIV risk behaviors and validity of self-reported recent drug use. Assessment 1994;1:383-92.
52. Needle RN, Fisher DG, Weatherby N, et al. Reliability of self-reported HIV risk behaviors of drug users. Psychology Addict Behav 1995;9:242-250.